Thomas Frederik Schmidt
Chief Financial OfficerMr. Thomas Frederik Schmidt, M.Sc., serves as Chief Financial Officer at Evaxion A/S (formerly known as Evaxion Biotech A/S) since July 2025 and was its Interim Chief Financial Officer since November 01, 2024 until July 2025. He joined Evaxion in November 2024. He served as Chief Financial Officer at Ambu A/S since June 1, 2022 and also served as its Executive vice President since 2022. He has extensive finance and management experience in the Roche Group. He joins Ambu from a position as General Manager of Roche Pharma Switzerland AG. Prior to that, he was CFO of Roche Pharma AG in Germany, a company with annual revenues of EUR 2bn (DKK 15bn) and Vice President of Finance in Europe. He has also served as the Senior Vice President for Roche Professional Diagnostics, a global player focused on bringing innovative diagnostic solutions to healthcare professionals. He started his career working as an auditor for Price Waterhouse. He holds Master of Science in Business Economics and Auditing from Copenhagen Business School.
Positions
- Company NameEvaxion A/SStock CodeEVAXPositionChief Financial OfficerColleagues
- HKHelen Katrina Tayton-MartinChief Executive Officer
- MSMarianne SogaardIndependent Chairwoman of the Board
- AHAndreas Holm MattssonFounder & Chief AI Officer
- BRBirgitte RonoChief Scientific Officer & COO
- BOBenjamin Ole WolthersVice President of Clinical Development
- RPRoberto Prego PinedaIndependent Director
- LHLars HoltugIndependent Director
- JSJeffrey S. WeberMember of Advisory Board
- SBSoren BrunakMember of Advisory Board
